Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 1014-1020

  Demokan, Semra ^a,b   Chuang, Alice Y ^b   Pattani, Kavita M ^b   Sidransky, David ^b   Koch, Wayne ^b   Califano, Joseph A ^b,c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Candidate gene approach; Head and neck cancer; Methylation; Nucleolar protein 4

Indexed keywords

NUCLEOLAR PROTEIN 4; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALX3 GENE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EBF3 GENE; EPIGENETICS; FEMALE; FUSSEL18 GENE; GBX2 GENE; GENE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HMX2 GENE; HUMAN; HUMAN TISSUE; IRX1 GENE; LHX6 GENE; LRRC3B GENE; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; NOL4 GENE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SALIVA; SEPT9 GENE; SLC5A8 GENE; SOCS3 GENE; TUMOR SUPPRESSOR GENE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC VARIATION; HEAD AND NECK NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892375686     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2927     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196, 1998.
3. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T and Cairns P: Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10: 6189-6193, 2004.
4. Leonhardt H and Cardoso MC: DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem Suppl 35: 78-83, 2000.
5. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
6. Yamashita K, Upadhyay S, Osada M, et al: Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495, 2002.
7. Bennett KL, Karpenko M, Lin MT, et al: Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 68: 4494-4499, 2008.
8. Bennett KL, Lee W, Lamarre E, et al: HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas. Genes Chromosomes Cancer 49: 319-326, 2010.
9. Estécio MR, Youssef EM, Rahal P, et al: LHX6 is a sensitive methylation marker in head and neck carcinomas. Oncogene 25: 5018-5026, 2006.
10. Pierconti F, Martini M, Pinto F, et al: Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate 71: 318-325, 2011.
11. Isomoto H: Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing. Digestion 79 (Suppl 1): 2-8, 2009.
12. Fourouclas N, Li J, Gilby DC, et al: Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 93: 1635-1644, 2008.
13. Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C and Larocca LM: Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer 123: 2955-2960, 2008.
14. Weber A, Hengge UR, Bardenheuer W, et al: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24: 6699-6708, 2005.
15. Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD, Sterneck E and Ganapathy V: SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 66: 11560-11564, 2006.
16. Zhao LY, Niu Y, Santiago A, Liu J, Albert SH, Robertson KD and Liao D: An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. Cancer Res 66: 9445-9452, 2006.
17. Yu YY, Ji J, Lu Y, Bu L, Liu BY, Zhu ZG and Lin YZ: High-resolution analysis of chromosome 5 and identification of candidate genes in gastric cancer. Zhonghua Zhong Liu Za Zhi 28: 84-87, 2006 (In Chinese).
18. Jönsson G, Staaf J, Olsson E, et al: High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46: 543-558, 2007.
19. Burrows JF, Chanduloy S, McIlhatton MA, et al: Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol 201: 581-588, 2003.
20. Amir S, Wang R, Matzkin H, Simons JW and Mabjeesh NJ: MSF-A interacts with hypoxia-inducible factor-1α and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. Cancer Res 66: 856-866, 2006.
21. Endo S, Zeng Q, Burke NA, et al: TGF-α antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther 7: 1906-1914, 2000.
22. Le QT, Kong C, Lavori PW, et al: Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69: 167-175, 2007.
23. Sánchez-Elsner T, Botella LM, Velasco B, Corbí A, Attisano L and Bernabéu C: Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276: 38527-38535, 2001.
24. Bernard PS and Wittwer CT: Real-time PCR technology for cancer diagnostics. Clin Chem 48: 1178-1185, 2002.
25. Eads CA, Danenberg KD, Kawakami K, et al: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32, 2000.
26. Cottrell SE and Laird PW: Sensitive detection of DNA methylation. Ann NY Acad Sci 983: 120-130, 2003.
27. Jerónimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG and Sidransky D: Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93: 1747-1752, 2001.
28. Tokumaru Y, Yamashita K, Osada M, et al: Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 64: 5982-5987, 2004.
29. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431, 2002.
30. Park HL, Kim MS, Yamashita K, et al: DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer 122: 2498-2502, 2008.
31. Ueki N, Kondo M, Seki N, Yano K, Oda T, Masuho Y and Muramatsu M: NOLP: identification of a novel human nucleolar protein and determination of sequence requirements for its nucleolar localization. Biochem Biophys Res Commun 252: 97-102, 1998.
32. Wang SS, Smiraglia DJ, Wu YZ, et al: Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res 68: 2489-2497, 2008.
33. Guo X, Liu W, Pan Y, et al: Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma. Oncogene 29: 3908-3920, 2010.
34. Bennett KL, Romigh T and Eng C: Disruption of transforming growth factor-β signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. Cancer Res 69: 9301-9305, 2009.
35. Demokan S, Chuang AY, Chang X, et al: Identification of guanine nucleotide-binding protein γ-7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling. Int J Oncol 42: 1427-1436, 2013.